Edition:
United Kingdom

Diplomat Pharmacy Inc (DPLO.N)

DPLO.N on New York Stock Exchange

25.73USD
22 Jan 2018
Change (% chg)

$0.51 (+2.02%)
Prev Close
$25.22
Open
$25.29
Day's High
$25.86
Day's Low
$25.29
Volume
105,094
Avg. Vol
187,181
52-wk High
$26.18
52-wk Low
$12.76

Latest Key Developments (Source: Significant Developments)

Diplomat Reaffirms 2017 Guidance And Provides Preliminary 2018 Outlook
Friday, 5 Jan 2018 

Jan 5 (Reuters) - Diplomat Pharmacy Inc ::DIPLOMAT PHARMACY INC - ‍JEFF PARK, HAS BEEN APPOINTED INTERIM CHIEF EXECUTIVE OFFICER, EFFECTIVE IMMEDIATELY​.DIPLOMAT PHARMACY INC - PHIL HAGERMAN TO CONTINUE SERVICE ON BOARD AND BECOME CHAIRMAN EMERITUS.DIPLOMAT PHARMACY INC - BOARD HAS APPOINTED BEN WOLIN, INDEPENDENT LEAD DIRECTOR, AS CHAIRMAN OF DIPLOMAT BOARD, EFFECTIVE IMMEDIATELY.DIPLOMAT INITIATES CEO TRANSITION; REAFFIRMS 2017 GUIDANCE AND PROVIDES PRELIMINARY 2018 OUTLOOK.DIPLOMAT PHARMACY - ‍PARK'S APPOINTMENT FOLLOWS RETIREMENT OF PHIL HAGERMAN.DIPLOMAT PHARMACY INC - IN 2018, DIPLOMAT PRELIMINARILY EXPECTS REVENUE IN RANGE OF $5.3 TO $5.6 BILLION.  Full Article

Diplomat Reaffirms 2017 Guidance, Provides Preliminary 2018 Outlook
Friday, 5 Jan 2018 

Jan 5 (Reuters) - Diplomat Pharmacy Inc ::- EXPECTS 2017 REVENUE TO BE NEAR MIDDLE OF PREVIOUSLY PROVIDED RANGE.FY2018 EARNINGS PER SHARE VIEW $0.95, REVENUE VIEW $5.38 BILLION -- THOMSON REUTERS I/B/E/S.DIPLOMAT REAFFIRMS 2017 GUIDANCE, PROVIDES PRELIMINARY 2018 OUTLOOK.SEES FY 2018 REVENUE UP ABOUT 20 PERCENT.SEES FY 2018 REVENUE $5.3 BILLION TO $5.6 BILLION.- IN 2018, EXPECTS ADJUSTED EBITDA IN RANGE OF $164 TO $170 MILLION.  Full Article

Diplomat Completes Acquisition Of LDI Integrated Pharmacy Services
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - Diplomat Pharmacy Inc ::DIPLOMAT COMPLETES ACQUISITION OF LDI INTEGRATED PHARMACY SERVICES, SECURES NEW CREDIT FACILITIES.DIPLOMAT PHARMACY INC - ENTERED INTO NEW $800 MILLION SENIOR SECURED CREDIT FACILITIES.DIPLOMAT PHARMACY - $800 MILLION FINANCING COMPRISED OF $250 MILLION REVOLVING CREDIT FACILITY, $150 MILLION TERM LOAN A FACILITY, $400 MILLION TERM LOAN B FACILITY.DIPLOMAT PHARMACY - PROCEEDS OF DEBT FINANCING WILL BE USED TO FINANCE LDI DEAL, REFINANCE DIPLOMAT'S CURRENT INDEBTEDNESS, AMONG OTHERS.  Full Article

Diplomat to acquire LDI Integrated Pharmacy Services
Wednesday, 15 Nov 2017 

Nov 15 (Reuters) - Diplomat Pharmacy Inc :Diplomat to acquire LDI Integrated Pharmacy Services.Diplomat to acquire LDI Integrated Pharmacy Services.Diplomat Pharmacy Inc - ‍will pay LDI $515 million cash and approximately $80 million in diplomat common stock​.Diplomat Pharmacy Inc - ‍LDI is expected to generate approximately $388 million in revenue and $41 million in adjusted EBITDA in 2017​.Diplomat Pharmacy Inc - ‍cash portion of acquisition is expected to be funded by diplomat's new $795 million senior secured credit facility​.  Full Article

Diplomat Pharmacy announces 3rd quarter financial results
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Diplomat Pharmacy Inc :Diplomat announces 3rd quarter financial results.Q3 adjusted earnings per share $0.25.Q3 earnings per share $0.01.Q3 revenue $1.125 billion versus I/B/E/S view $1.16 billion.Q3 earnings per share view $0.15 -- Thomson Reuters I/B/E/S.Sees FY 2017 adjusted earnings per share $0.82 to $0.87.Sees FY 2017 earnings per share $0.15 to $0.20.Sees FY 2017 revenue $4.4 billion to $4.6 billion.FY2017 earnings per share view $0.75, revenue view $4.52 billion -- Thomson Reuters I/B/E/S.Diplomat Pharmacy Inc - ‍resolved arbitration with CVS and have transitioned from a PSAO contract to a direct contract with CVS​.  Full Article

Diplomat Pharmacy to acquire Pharmaceutical Technologies Inc
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Diplomat Pharmacy Inc :Diplomat Pharmacy - entered agreement to acquire Pharmaceutical Technologies Inc, doing business as National Pharmaceutical Services.Diplomat Pharmacy - under the terms of the agreement, Diplomat will pay NPS $31 million cash and $16 million in Diplomat common stock‍​.  Full Article

Diplomat Pharmacy Q2 adjusted earnings per share $0.23
Tuesday, 9 Aug 2016 

Diplomat Pharmacy Inc : Diplomat announces 2nd quarter financial results . Q2 earnings per share $0.13 . Q2 revenue $1.089 billion versus i/b/e/s view $1.12 billion . Q2 adjusted earnings per share $0.23 . Q2 earnings per share view $0.21 -- Thomson Reuters I/B/E/S . Sees fy 2016 adjusted earnings per share $0.90 to $0.95 . Fy2016 earnings per share view $0.93, revenue view $4.76 billion -- Thomson Reuters I/B/E/S .For full-year 2016, we are maintaining our previous financial guidance for revenue and adjusted ebitda.  Full Article

Diplomat Pharmacy says to dispense epclusa for treatment of chronic Hepatitis C
Tuesday, 28 Jun 2016 

Diplomat Pharmacy Inc : Says to dispense epclusa for treatment of chronic Hepatitis C .Says epclusa is manufactured by Gilead Sciences.  Full Article

Diplomat Q1 EPS $0.24
Monday, 9 May 2016 

Diplomat Pharmacy Inc : Fy2016 earnings per share view $0.88, revenue view $4.51 billion -- Thomson Reuters I/B/E/S . Diplomat announces 1st quarter financial results . Q1 adjusted earnings per share $0.23 . Q1 earnings per share $0.24 . Sees fy 2016 adjusted earnings per share $0.88 to $0.95 . Sees fy 2016 revenue $4.5 billion to $4.9 billion . Q1 revenue $996 million versus i/b/e/s view $982.9 million .Q1 earnings per share view $0.18 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Diplomat Pharmacy Says Dispensing Advanced Kidney Treatment, CABOMETYX

* DIPLOMAT PHARMACY INC - ‍IS DISPENSING EXELIXIS' LIMITED-DISTRIBUTION TREATMENT CABOMETYX NOW WITH AN EXPANDED INDICATION​ Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)